Michael H. Davidson to Osteoporosis, Postmenopausal
This is a "connection" page, showing publications Michael H. Davidson has written about Osteoporosis, Postmenopausal.
Connection Strength
0.105
-
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002 Dec 03; 137(11):875-83.
Score: 0.056
-
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2001 05; 86(5):1890-7.
Score: 0.050